Athira Pharma, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 27.82 million compared to USD 20.98 million a year ago. Basic loss per share from continuing operations was USD 0.73 compared to USD 0.56 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.45 USD | -3.92% | -4.30% | +0.82% |
05-15 | Athira Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
04-15 | Athira Pharma, Inc. Appoints Javier San Martin, M.D., as Chief Medical Officer | CI |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+0.82% | 97.73M | |
+46.19% | 56.65B | |
-6.14% | 39.44B | |
+39.19% | 39.03B | |
-6.65% | 26.86B | |
+12.33% | 26.75B | |
-21.78% | 19.03B | |
-0.35% | 12.28B | |
+24.18% | 12.26B | |
+28.38% | 12.04B |
- Stock Market
- Equities
- ATHA Stock
- News Athira Pharma, Inc.
- Athira Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023